By Karen Blum
ORLANDO, Fla.—The year 2023 was big for biosimilars, which saw eight such products added to the market for adalimumab (Humira, AbbVie). The space is continuing to grow, panelists said during the AMCP Nexus 2023 meeting, with 2025 expected to be another strong year for the addition of new biosimilars.
OCTOBER 18, 2023